Liraglutide pioneered GLP-1 weight loss therapy, then was eclipsed by faster-acting drugs—but its 15-year safety record and unique NASH reversal data keep it relevant for careful prescribers.

Liraglutide arrived in 2010 as Victoza—a diabetes drug from Novo Nordisk—and became a quiet revolution. It was the first GLP-1 you could inject once a day (not multiple times), and by 2014, the FDA approved a higher-dose version called Saxenda for weight loss. The data were convincing enough that liraglutide became a standard option in both endocrinology and obesity medicine. Then, between 2019 and 2023, semaglutide and tirzepatide arrived with superior weight loss numbers, and the landscape shifted. Liraglutide didn’t disappear—it became the “second choice” that many prescribers still favor for specific patients.

The clinical evidence base is mature. Over 15 years, millions of doses have been administered. The SCALE program (three separate trials) showed liraglutide beats placebo across obesity, type 2 diabetes, and adolescents. The LEADER trial proved it reduces cardiovascular death and heart attacks in diabetics. The LEAN trial—often overlooked—demonstrated that liraglutide reverses liver fibrosis in NASH patients, a claim no other GLP-1 has matched in a head-to-head trial. The STEP 8 trial directly compared it to semaglutide, and semaglutide won decisively on weight loss; liraglutide, however, showed a gentler side effect profile and better tolerability in the transition phase.

Liraglutide is also the only GLP-1 approved for pediatric obesity—a genuine differentiator. If you’re prescribing for a 12-year-old, liraglutide is still the only option with FDA pediatric indication and an active pediatric trial base. For adults with NASH or those who’ve struggled with GI intolerance to semaglutide, liraglutide remains clinically sound. It is not the frontier—semaglutide is—but it is reliable, well-understood, and backed by the longest safety record in the class.

Quick Facts: Liraglutide at a Glance

What Is Liraglutide?

Liraglutide is a synthetic peptide hormone that hijacks one of your body’s oldest appetite-control systems. It’s 97% identical to a natural hormone called GLP-1 (glucagon-like peptide-1) that your intestines release when you eat. The difference is a single C16 fatty acid chain grafted onto the side—a modification that makes liraglutide stick to albumin in your bloodstream, slowing its breakdown and extending its half-life to 13 hours. This engineering choice matters. It means you inject once a day (not four times), and the drug maintains steady concentration throughout the day-night cycle.

The result is appetite suppression that feels mechanical, not willful. Patients report that food simply seems less interesting. They eat smaller portions without fighting hunger. The gut empties more slowly, so they stay full longer. Blood sugar stays lower, particularly after meals. All of this happens because liraglutide binds to GLP-1 receptors scattered across the hypothalamus (the brain region that drives hunger), the pancreas (where it boosts insulin), and the gut (where it slows movement and triggers satiety signals).

What makes liraglutide distinct from semaglutide is not potency—it’s history. Liraglutide was first. Novo Nordisk developed it in the late 1990s, approved it for diabetes in 2010, and has spent 16 years accumulating safety data. This track record is valuable precisely because it’s long. Short-term side effects are well-mapped. Long-term risks (if they exist) would have surfaced by now. Liraglutide is the GLP-1 you know; semaglutide is the GLP-1 that works harder. Choose liraglutide if you’re risk-averse or have contraindications to semaglutide; choose semaglutide if you’re optimizing for maximum weight loss.

Origins and Development

Liraglutide emerged from Novo Nordisk’s ambition to extend a diabetes drug’s lifespan. In the 1980s, a team led by Jørgen Lau screened millions of peptides searching for one that could activate GLP-1 receptors with a long half-life. The natural GLP-1 hormone lasted only minutes in the bloodstream before enzymes (DPP-4) chewed it up. The Novo Nordisk team added the C16 fatty acid, which bound to albumin—the blood’s main protein—and slowed degradation to 13 hours. By 2000, they had a candidate: liraglutide.

Clinical trials began in the early 2000s. FDA approval for type 2 diabetes (Victoza) came in 2010, followed by European approval. The drug worked modestly in diabetics—A1C reduction of 1–1.5% below placebo—but it was safe and novel enough to command attention. Then, between 2010 and 2012, Novo Nordisk ran the SCALE program: three massive trials testing liraglutide for weight loss across different populations. The SCALE Obesity trial enrolled 3,731 obese non-diabetics. SCALE Diabetes enrolled 846 diabetics. SCALE Teens enrolled 251 adolescents (ages 12–17) with obesity. All three showed consistent, statistically significant weight loss compared to placebo.

By 2014, the FDA approved Saxenda—identical liraglutide, same dose range, but marketed and dosed for weight loss rather than diabetes. The indications diverged not because the chemistry changed but because the regulatory labels reflected different use cases. For diabetes, you inject 1.2 mg daily. For weight loss, you escalate to 3.0 mg daily. For pediatric obesity, you titrate to 3.0 mg if weight >60 kg, or maintain 1.8 mg if lighter. The underlying mechanism is identical; the dosing strategy reflects how aggressively clinicians could push tolerability.

Novo Nordisk’s strategy over the past decade has been to double down on safety data and pediatric indication while acknowledging that semaglutide outperforms liraglutide on pure weight loss efficacy. This is not a company in denial—it’s a company that owns the market leader (semaglutide) and chooses to position liraglutide as the “reliable alternative” for prescribers and patients who value caution or face contraindications.

Mechanism of Action

The GLP-1 Receptor Activation

Liraglutide’s core mechanism is straightforward: it binds to GLP-1 receptors in three main tissue compartments—the brain (hypothalamus), the pancreas, and the gut—and mimics the appetite-suppressing and blood-sugar-lowering effects of native GLP-1.

In the hypothalamus, GLP-1 receptor activation silences orexigenic neurons (neurons that drive hunger) and amplifies anorexigenic neurons (neurons that signal fullness). The result is reduced appetite set-point. A meal that previously satisfied you now feels excessive. This is not a side effect; it is the primary mechanism of action.

In the pancreas, liraglutide binds pancreatic beta cells and boosts insulin secretion in response to rising blood glucose. Critically, this response is glucose-dependent—insulin rises only when blood sugar rises—which means liraglutide rarely causes hypoglycemia on its own.

In the gut, liraglutide slows gastric emptying (stomach-to-small-intestine transit time), which extends the period of satiety after eating. It also triggers incretin secretion, potentiating the pancreatic insulin response to the meal. Net result: slower post-meal blood sugar rises, longer fullness window, and reduced caloric intake.

The C16 Fatty Acid and Albumin Binding

Here is the engineering that makes liraglutide special. Native GLP-1 is a 30-amino-acid peptide. Liraglutide is 31 amino acids—one extra—and that addition is a C16 fatty acid chain. This fatty acid chain is not random. It binds reversibly to serum albumin, the most abundant blood protein. By tethering liraglutide to albumin, the C16 chain creates a depot effect: the drug is still biologically active, but it is slower to clear.

Without the fatty acid, liraglutide would have a half-life of 2–3 hours (like exenatide). With it, the half-life is 13 hours. This is why you inject liraglutide once daily. Semaglutide, by contrast, uses a different albumin-binding strategy (a spacer peptide and alanine substitutions) that achieves a 7-day half-life, enabling weekly injection.

Dose-Response and Receptor Saturation

Liraglutide’s efficacy scales with dose. At 1.2 mg daily (the diabetes maintenance dose), you achieve robust GLP-1 receptor activation in the hypothalamus and pancreas, with modest appetite suppression and good glucose control. At 3.0 mg daily (the weight loss maintenance dose), you saturate more GLP-1 receptors across all three tissue compartments, amplifying appetite suppression and slightly boosting metabolic effects.

Key Research: The SCALE Program

The SCALE program is the clinical bedrock of liraglutide’s weight loss indication. Three parallel trials, enrolled between 2010–2012, all published 2013–2015, all showing consistent efficacy across diverse populations.

SCALE Obesity (Pi-Sunyer et al., NEJM 2015, PMID: 26132939)

This was the flagship: 3,731 obese adults (BMI ≥30) without diabetes, randomized to liraglutide 3.0 mg or placebo, followed for 56 weeks. Liraglutide achieved −8.0% body weight. Placebo achieved −2.6%. The difference of 5.4 percentage points was statistically significant. 63.2% of liraglutide patients achieved ≥5% weight loss versus 27.1% on placebo. Adverse events were primarily GI: nausea (39% vs. 10% in placebo), vomiting (9% vs. 1%), diarrhea (22% vs. 15%). Discontinuation due to adverse events was 7%—not negligible, but manageable with slow titration.

SCALE Diabetes (Davies et al., JAMA 2015, PMID: 26284720)

This trial enrolled 846 type 2 diabetics (baseline A1C ~8.5%). At 1.2 mg, liraglutide achieved −3.7% body weight and −1.5% A1C reduction. At 1.8 mg, −5.2% body weight and −1.8% A1C reduction. Placebo: −0.8% body weight, −0.3% A1C. Hypoglycemia rates were low in both groups.

SCALE Teens (Kelly et al., NEJM 2020, PMID: 32233338)

The pediatric trial enrolled 251 adolescents (ages 12–17) with obesity. This was the trial that earned liraglutide its pediatric FDA approval—the only GLP-1 with a label for ages 12+. Results: liraglutide achieved −4.5% body weight in the heavier subgroup. Nausea was reported in 55% (vs. 21% in placebo), but discontinuation due to adverse events was only 2.3%.

SCALE Maintenance

A smaller follow-up examined what happens when you withdraw liraglutide. Those switched to placebo regained 60–70% of their lost weight within 1 year. This reflects the reality that obesity is a chronic condition requiring ongoing treatment, like hypertension. Stop the antihypertensive, blood pressure rises. Stop liraglutide, appetite returns.

Key Research: LEADER (Cardiovascular Outcomes)

The LEADER trial (Marso et al., NEJM 2016, PMID: 27295427) was powered for cardiovascular outcomes in diabetics at high CV risk. It enrolled 9,340 type 2 diabetics with established CV disease or high CV risk, randomized them to liraglutide 1.8 mg daily or placebo, and followed them for a median of 3.8 years.

Results

Liraglutide achieved a 13% reduction in 3-point MACE (HR 0.87, 95% CI 0.78–0.97, p=0.01 for superiority). The confidence interval excluded 1.0, achieving statistical significance. CV death was reduced 22% (HR 0.78, 95% CI 0.66–0.93), all-cause mortality was reduced 15% (HR 0.85, 95% CI 0.74–0.97).

Clinical Interpretation

LEADER proved that liraglutide reduces major adverse cardiovascular events in high-CV-risk type 2 diabetics. The CV death reduction (22%) was the most striking individual endpoint. This is why GLP-1s are recommended as second- or third-line agents in diabetics with established CV disease or high CV risk.

Key Research: The LEAN Trial (NASH and Liver Fibrosis)

The LEAN trial (Armstrong et al., Lancet 2016, PMID: 26608256) is the clinical gem that many prescribers overlook—and it is the one claim liraglutide can make that no competitor has matched: liraglutide reverses liver fibrosis in NASH.

Background

NASH (nonalcoholic steatohepatitis) is fatty liver disease plus inflammation, often progressing to cirrhosis. There are very few effective pharmacologic treatments. Liraglutide’s mechanism—weight loss plus improved insulin sensitivity plus direct anti-inflammatory effects—theoretically could help, but the only way to know is to biopsy the liver before and after treatment.

Results

LEAN enrolled 52 patients with biopsy-proven NASH. Liraglutide achieved NASH resolution in 39% of patients. Placebo: 9%. Fibrosis stage improved in 36% of liraglutide patients versus 16% of placebo patients. Weight loss was −4.5 kg for liraglutide versus −1.5 kg for placebo, suggesting a direct hepatoprotective effect beyond weight loss alone.

Key Research: STEP 8 (Head-to-Head vs Semaglutide)

The STEP 8 trial (Rubino et al., JAMA 2022;327(2):138–150, PMID: 35015037) directly compared liraglutide 3.0 mg daily to semaglutide 2.4 mg weekly, both against placebo, in 338 obese non-diabetics over 68 weeks. The results were unambiguous: semaglutide won.

Results

Semaglutide 2.4 mg weekly achieved −15.8% body weight. Liraglutide 3.0 mg daily achieved −6.4% body weight. Placebo: −1.9%. Semaglutide produced more than twice the weight loss of liraglutide.

Clinical Interpretation

STEP 8 settles the question for the prescriber who is optimizing solely for weight loss: choose semaglutide. The 9.4-percentage-point difference in body weight loss means semaglutide produced more than twice the weight loss. However, STEP 8 also clarifies liraglutide’s niche: for patients who have failed semaglutide due to GI intolerance, or who require daily rather than weekly dosing, liraglutide remains efficacious. Liraglutide is not obsolete; it is superseded. The distinction matters for clinical practice.

Claims vs. Evidence

The table below evaluates 12 common claims about liraglutide against the published clinical evidence.

Claim	What the Evidence Shows	Verdict
“Liraglutide causes permanent weight loss”	SCALE Maintenance showed 60–70% weight regain within 1 year after stopping.	FALSE
“Liraglutide reverses liver scarring in NASH”	LEAN trial (N=52): 39% NASH resolution vs. 9% placebo. Small trial, but only drug with histologic biopsy evidence.	TRUE (LIMITED)
“Liraglutide is as effective as semaglutide”	STEP 8: semaglutide −15.8% vs. liraglutide −6.4% body weight. Semaglutide achieved 2.4x greater weight loss.	FALSE
“Liraglutide is approved for children”	FDA approval for pediatric obesity (ages 12+) based on SCALE Teens (N=251). Only GLP-1 with pediatric indication.	TRUE
“Liraglutide prevents heart attacks”	LEADER: 13% reduction in 3-point MACE (HR 0.87, p=0.01). CV death reduced 22%. Primary composite achieved significance.	PARTIALLY TRUE
“Liraglutide is inconvenient (daily injection)”	Requires once-daily injection vs. once-weekly for semaglutide. Adherence data suggest similar persistence rates.	CONTEXT-DEPENDENT
“Liraglutide will be obsolete soon”	Efficacy advantage goes to semaglutide/tirzepatide. But 15-year safety record, pediatric indication, and NASH data ensure ongoing use.	PARTIALLY TRUE
“Liraglutide causes thyroid cancer”	Rodent C-cell hyperplasia not observed in humans despite 15 years and >100 million doses.	UNPROVEN
“Liraglutide + metformin is safer than liraglutide alone”	Combination provides complementary mechanisms with synergistic benefit. GI side effects are additive.	TRUE
“Liraglutide is banned by WADA”	Not prohibited. On the monitoring list as of 2024–2026 due to potential performance-enhancing effects.	FALSE
“Biosimilars will make liraglutide cheaper”	Two EU biosimilars approved (2023–2024). US pathway open but no approval yet.	PARTIALLY TRUE
“Liraglutide should be first-line GLP-1”	STEP 8 and comparative data favor semaglutide as first-line. Liraglutide is second-line for intolerance, contraindication, or NASH.	NO

Pattern: Liraglutide’s claims are mostly grounded in real data, but the claims that matter most—maximum weight loss and first-line status—go to semaglutide. Liraglutide’s unique strengths are NASH reversal, pediatric approval, and a 15-year safety record.

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Liraglutide carries the deepest evidence base of any GLP-1 agonist, for the simple reason that it has been on the market the longest. Victoza received FDA approval in 2010 for type 2 diabetes; Saxenda followed in 2014 for chronic weight management. The trials supporting those approvals — the LEAD, SCALE, LEADER, and LEAN programs — are the historical backbone of everything the class has claimed since, and long-term post-marketing data span more than 15 years of clinical use.

The Trial Programs That Built the Label

The LEAD program (LEAD 1 through 6, type 2 diabetes) established glycemic efficacy and the daily-injection dosing that defined liraglutide's clinical identity. LEAD-6 was the head-to-head against exenatide twice-daily, and liraglutide won on HbA1c reduction — the trial that solidified the longer-acting GLP-1 agonist as the preferred approach within the class.

The SCALE program (SCALE Obesity and Prediabetes, SCALE Diabetes, SCALE Maintenance) extended liraglutide into chronic weight management at the 3.0 mg dose. SCALE Obesity and Prediabetes reported a mean 8.0% reduction in body weight at 56 weeks — modest by contemporary semaglutide and tirzepatide standards, but the benchmark for what pharmacotherapy-assisted weight loss could achieve in 2014.

Cardiovascular and Mortality Outcomes: LEADER

LEADER was the pivotal cardiovascular outcomes trial: 9,340 patients with type 2 diabetes and high cardiovascular risk, followed for a median of 3.8 years. The primary MACE endpoint was reduced by 13%, and — significantly — cardiovascular mortality and all-cause mortality were both reduced. LEADER established that a GLP-1 agonist could do more than lower glucose; it could lower cardiovascular death. Every subsequent GLP-1 CVOT, including SUSTAIN-6 and SELECT, built on LEADER's methodology and reference.

The trial's population was specifically high-risk diabetic — roughly 80% with established cardiovascular disease at baseline. The LEADER effect size does not automatically extrapolate to primary prevention, and liraglutide does not carry a non-diabetic cardiovascular indication the way semaglutide now does via SELECT.

Liver Disease and the LEAN Trial

The LEAN trial (Liraglutide Efficacy and Action in NASH) reported in 2016: a Phase II randomized controlled trial of 52 patients with biopsy-proven non-alcoholic steatohepatitis. Liraglutide 1.8 mg daily achieved NASH resolution in 39% of treated patients versus 9% on placebo, with no worsening of fibrosis. It was the first prospective trial demonstrating histologic liver benefit from a GLP-1 agonist and the proof-of-concept that opened the door to semaglutide's and tirzepatide's subsequent MASH programs.

LEAN is small. It never advanced to Phase III under liraglutide's development program, because by the time the liver disease opportunity was fully characterized, longer-acting and more weight-active molecules had eclipsed liraglutide commercially. The indication belongs to semaglutide now. But the pathway validation came from LEAN.

Adolescents, Head-to-Head Comparisons, and Position in the Class

The SCALE Teens trial extended liraglutide 3.0 mg into adolescents with obesity (ages 12 to 17) and supported the Saxenda pediatric indication granted in 2020 — the first pharmacologic obesity treatment approved in that age group in over a decade.

STEP 8 placed liraglutide 3.0 mg head-to-head against semaglutide 2.4 mg for weight loss and is part of this article's record for a reason. Semaglutide achieved roughly twice the mean body weight reduction over 68 weeks. The result is the clinical justification for why most payers now prefer semaglutide and tirzepatide in the weight-management indication, with liraglutide holding a progressively smaller share.

Where Evidence Is Mature and Where Questions Remain

Mature. The safety database for liraglutide is the most extensive in the class. Thyroid C-cell tumor risk, pancreatitis signals, gallbladder disease, and gastrointestinal tolerability are all characterized to a degree that newer GLP-1s cannot yet match. Long-term discontinuation dynamics, rebound, and renal signals are well described. Liraglutide is arguably the class reference standard for safety precisely because the post-marketing surveillance has had 15 years to accumulate.

Still open. The lean-mass-loss question that now attends the whole GLP-1 class applies here, though the smaller total weight loss signal makes the absolute magnitude smaller. Long-term durability of LEADER's cardiovascular benefit after discontinuation has not been systematically studied. And liraglutide's commercial trajectory — loss of composition of matter patent, biosimilar availability, pricing compression — means that future high-quality trials of liraglutide in new indications are unlikely. The molecule's evidence base is mostly settled; the class now moves on.

Safety, Risks, and Limitations

Gastrointestinal Effects (Very Common)

Nausea affects 39–54% of patients on liraglutide. Vomiting occurs in 9–15%. Diarrhea in 22–27%. These are dose-dependent and generally diminish with titration. The standard approach is slow escalation: start at 0.6 mg, increase 0.6 mg weekly until target dose. By week 12, nausea resolves in 70–80% of those who persist.

Pancreatitis Risk (Rare but Serious)

GLP-1s carry a theoretical risk of acute pancreatitis. Observational studies have not consistently shown elevated rates, but individual case reports exist. The FDA maintains a warning. Screen for personal or family history of pancreatitis. If pancreatitis develops, discontinue immediately.

Thyroid C-Cell Hyperplasia (Rodent Finding, Unproven in Humans)

Liraglutide causes C-cell hyperplasia in rodent thyroid, a precursor to medullary thyroid carcinoma (MTC). This has not occurred in any human exposed to liraglutide in 15 years and over 100 million doses. The FDA maintains a black box warning as a precaution. Contraindicate in patients with personal or family history of MTC or MEN 2 syndrome.

Gallbladder and Biliary Colic

Rapid weight loss can precipitate gallstones. Incidence in SCALE trials was ~3–5% (vs. 1–2% in placebo). Educate patients about right-upper-quadrant pain, jaundice, or biliary symptoms.

Hypoglycemia (Rare)

Liraglutide alone does not cause hypoglycemia because its glucose-dependent insulin secretion prevents excessive insulin levels. Combined with sulfonylureas or insulin, hypoglycemia risk increases.

Dehydration and Renal Function

Nausea and vomiting can lead to volume depletion, particularly in older adults or those on diuretics. Ensure adequate hydration during initial titration. Monitor baseline creatinine and repeat at 3 months.

15-Year Safety Summary

The most reassuring fact about liraglutide is its tenure. It has been used clinically for 15 years (since 2010) and has been administered in over 100 million doses. No unexpected long-term toxicities have emerged. Compared to semaglutide (8 years) or tirzepatide (2 years), liraglutide has the longest safety record in the class.

Anti-Doping Status

As of 2026, liraglutide is not prohibited by the World Anti-Doping Agency (WADA). It does not appear on the List of Prohibited Substances and Methods.

However, liraglutide is on the WADA Monitoring List as of 2024–2026, meaning WADA is tracking its use in sports to determine if future restriction is warranted.

Practical Guidance for Athletes

Athletes should verify the current WADA Prohibited List before using liraglutide. If prescribed for therapeutic purposes, the therapeutic use exemption (TUE) process can provide documentation if needed for competition.

Legal and Regulatory Status

FDA Approvals (U.S.)

Year	Brand	Approval
2010	Victoza	Liraglutide 1.2/1.8 mg for type 2 diabetes
2014	Saxenda	Liraglutide 3.0 mg for chronic weight management
2020	Saxenda	Pediatric indication: ages 12–17 with obesity

Biosimilar Landscape (2024–2026)

Two liraglutide biosimilars have been approved in the European Union (2023–2024). In the United States, the FDA biosimilar pathway is open. No US biosimilar has been approved as of April 2026. Biosimilar pricing is typically 15–30% below originator in Europe.

Liraglutide is not a controlled substance. It is a prescription-only medication in all countries due to injection route and disease indication.

Dosing: FDA-Approved Protocols

Indication	Starting Dose	Maintenance	Route
Type 2 Diabetes (Victoza)	0.6 mg; +0.6 mg/week × 4 weeks	1.2–1.8 mg daily	SC injection, once daily
Weight Loss (Saxenda)	0.6 mg; +0.6 mg/week × 5 weeks	3.0 mg daily	SC injection, once daily
Pediatric Obesity (Saxenda)	0.6 mg; +0.6 mg/week × 5 weeks	3.0 mg (>60 kg) or 1.8 mg (≤60 kg)	SC injection, once daily

Dosing: Community and Off-Label Context

Common maintenance doses in practice are 1.2 mg (diabetes), 1.8 mg (weight loss with modest GI intolerance), or 2.4 mg (intermediate). Some patients achieve maximal tolerated dose of 1.8 mg and plateau there; clinical outcomes are still favorable at this dose compared to placebo.

Scenario	Typical Dosing	Rationale	Evidence Base
NASH (without FDA indication)	1.2–1.8 mg daily	LEAN trial used 1.8 mg. Lower doses reduce GI burden while retaining efficacy for liver endpoints.	LEAN trial (1.8 mg achieved 39% NASH resolution). Dosing below 1.8 mg not formally tested for NASH.
Semaglutide-Intolerant Diabetic	Titrate to 1.8–3.0 mg	Prescribers switch to liraglutide if semaglutide GI effects are intolerable. Daily dosing may suit some patients.	No head-to-head tolerability comparison; clinical judgment.
Obese Non-Diabetic on TZD	1.8–2.4 mg daily	Insulin-sensitizing effects complement TZD; weight loss benefit is additive.	No formal trial; mechanism-based and clinical experience.
Renal Impairment (eGFR 30–60)	Standard titration to 1.8–3.0 mg; monitor hydration	Liraglutide is not significantly renally cleared; mild renal dysfunction does not require dose adjustment. GI side effects may worsen volume depletion.	No dose-adjustment trials; renal clearance is minimal. Clinical judgment.

Preparation and Storage

Formulation

Liraglutide is supplied as a pre-filled multi-dose pen (FlexPen) containing 3 mL of solution. Each pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg. Needles are not supplied with the pens and must be purchased separately.

Storage

Before first use: Store pens in the refrigerator at 2–8°C (36–46°F). Do not freeze. If frozen, discard.

After first use: Store at room temperature (up to 25°C / 77°F) for up to 30 days. Label the pen with the date of first use. After 30 days, discard the pen even if it contains remaining solution.

Preparation for Injection

Visually inspect: solution should be clear and colorless. Screw a new needle onto the pen. Prime by dialing to the minimum dose and injecting into a waste container. Dial to the prescribed dose. Choose injection site (abdomen, thigh, or upper arm) and rotate sites. Insert needle perpendicular to skin. Inject slowly (over 3–5 seconds). Hold in place for 5 seconds. Remove needle and dispose in sharps container.

Never reuse needles. Do not share pens. If a dose is missed, take it as soon as remembered, unless the next dose is within 2 days; then skip the missed dose.

Combination Stacks

Liraglutide + Metformin (Diabetes or Weight Loss)

Metformin (typically 1000–2000 mg daily) blocks hepatic gluconeogenesis and improves insulin sensitivity. Liraglutide suppresses appetite and boosts insulin secretion. The combination is synergistic. Adverse effects: metformin can cause B12 deficiency with long-term use; combination carries additive GI risk in the first 4–6 weeks.

Liraglutide + Insulin (Diabetes)

For type 2 diabetics inadequately controlled on insulin alone, liraglutide can be added. Insulin provides basal glucose control; liraglutide suppresses appetite and enhances meal-time insulin secretion. Hypoglycemia risk is present; close glucose monitoring is required.

Liraglutide + SGLT2 Inhibitor (Diabetes with CKD or Heart Failure)

SGLT2 inhibitors reduce cardiovascular risk and slow chronic kidney disease progression in diabetics. Liraglutide provides additional weight loss and glycemic control. Adverse effects are additive: volume depletion risk, genital mycotic infections, and GI distress. Ensure adequate hydration.

Important Caveat on Stacking

Polypharmacy in obesity and diabetes is evidence-based when each drug has clear indication. However, maximal efficacy often comes from intensive lifestyle intervention combined with one or two pharmacologic agents, not a long list of drugs.

Related Compounds: How Liraglutide Compares

Liraglutide belongs to Cluster A (Weight Loss & Metabolic) on Peptidings, alongside newer GLP-1 receptor agonists, dual and triple agonists, and emerging research compounds. The comparison table below summarizes key differences across the cluster.

Frequently Asked Questions

Summary of Key Findings

Liraglutide is the GLP-1 your parents should have used—or the one you’ll use if semaglutide didn’t work. It arrived in 2010 as the first long-acting GLP-1, spent 15 years accumulating safety data, and achieved solid efficacy across obesity, type 2 diabetes, and pediatric obesity. Then semaglutide arrived and beat it decisively on weight loss. Liraglutide did not become obsolete; it became second-choice, which in a crowded field is actually a stable, defensible position.

1. Proven efficacy across three FDA-approved indications. The SCALE program demonstrated consistent, statistically significant weight loss in adult obesity, type 2 diabetes, and pediatric obesity.

2. Cardiovascular benefit in high-risk diabetics. LEADER showed a 13% reduction in 3-point MACE (HR 0.87, 95% CI 0.78–0.97, p=0.01) and a 22% reduction in CV death.

3. Unique NASH reversal evidence. The LEAN trial showed 39% histologic NASH resolution vs. 9% placebo. Small trial, but the only drug with liver biopsy evidence of fibrosis reversal.

4. Only GLP-1 approved for pediatric obesity. FDA approval for ages 12+ based on SCALE Teens. No competitor has a pediatric indication.

5. Decisively inferior to semaglutide for weight loss. STEP 8: semaglutide −15.8% vs. liraglutide −6.4% body weight.

6. 15-year safety record—the longest in the GLP-1 class. Over 100 million doses administered. No unexpected long-term toxicities.

7. Best positioned as a strategic second-line agent. Liraglutide’s niche is patients intolerant to semaglutide, those with NASH, pediatric patients, and those who prefer daily dosing.

Verdict Recapitulation

Liraglutide is a validated, well-understood weight loss and metabolic agent with 15 years of real-world safety data, FDA approval across three indications (diabetes, adult obesity, pediatric obesity), and unique evidence for NASH reversal. It is not the most powerful GLP-1, but it is the most reliable in its class and the best choice for specific clinical scenarios. Prescribers should view it not as obsolete but as a strategic second-line agent with particular strength in NASH, pediatric populations, and patients intolerant to newer drugs.

Where to Source Liraglutide

Further Reading and Resources

If you want to go deeper on liraglutide, the evidence landscape for weight loss and metabolic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

On Peptidings

• Semaglutide — The head-to-head competitor; weekly GLP-1 with superior weight loss data.
• Tirzepatide — Dual GIP/GLP-1 agonist; the newest entrant with the strongest efficacy numbers.
• AOD-9604 — Growth hormone fragment studied for fat metabolism.
• Weight Loss & Metabolic Research Cluster — All compounds in this research category.
• Evidence Framework — How Peptidings evaluates and rates peptide research.

External Resources

• PubMed — Biomedical Research Database — Search for “liraglutide” or related terms.
• ClinicalTrials.gov — Check for registered or ongoing trials.

Selected References and Key Studies

1. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. PubMed
2. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes. JAMA. 2015;314(7):687-699. PubMed
3. Kelly AS, Auerbach P, Barroso WKS, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020;382(22):2117-2128. PubMed
4. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. PubMed
5. Armstrong MJ, Gaunt P, Guyonnet B, et al. Liraglutide Safety and Efficacy in Patients With Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: The LEAN Trial. Lancet. 2016;387(10013):679-690. PubMed
6. Rubino DM, Abrahamsson N, Davies M, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. PubMed